From the brink of Nasdaq delisting last year due to non-compliance with the minimum bid price rule, this clinical-stage biotechnology company has made a remarkable comeback.
The company we are referring to is Monopar Therapeutics Inc. (MNPR), developing ALXN1840 for Wilson Disease and MNPR-101 as a novel radiopharmaceutical targeting uPAR (urokinase-type plasminogen activator receptor), which is expressed in numerous tumor types including pancreatic, breast, colorectal, and bladder.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com